ERAS Erasca, Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers.

$14.95  -0.23 (-1.52%)
As of 12/03/2021 11:23:09 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/15/2021
Outstanding shares:  121,250,375
Average volume:  239,664
Market cap:   $1,724,180,333
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    29479A108
ISIN:        US29479A1088
Sedol:      BNLYBF3
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.81
PS ratio:   0.00
Return on equity:   -31.93%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy